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MECP2 Mutations in Sporadic Cases of Rett Syndrome Are Almost
Exclusively of Paternal Origin
R. Trappe,1,* F. Laccone,1,* J. Cobilanschi,1 M. Meins,1 P. Huppke,2 F. Hanefeld,2 and W. Engel1
1Institute of Human Genetics, Georg-August Universita¨t Go¨ttingen, and 2Paediatric Department, Specialty Neuropaediatrics, Go¨ttingen,
Germany
Rett syndrome (RTT) is an X-linked neurodevelopmental disorder that apparently is lethal in male embryos. RTT
almost exclusively affects female offspring and, in 99.5% of all cases, is sporadic and due to de novo mutations
in the MECP2 gene. Familial cases of RTT are rare and are due to X-chromosomal inheritance from a carrier
mother. We analyzed the parental origin of MECP2 mutations in sporadic cases of RTT, by analysis of linkage
between the mutation in the MECP2 gene and intronic polymorphisms in 27 families with 15 different mutations,
and we found a high predominance of mutations of paternal origin in 26 of 27 cases ( ). The paternalP ! .001
origin was independent of type of mutation and was found for single-base exchanges as well as for deletions.
Parents were not of especially advanced age. We conclude that de novo mutations in RTT occur almost exclusively
on the paternally derived X chromosome and that this is most probably the cause for the high female:male ratio
observed in patients with RTT. Affected males recently have been described in a few cases of familial inheritance.
Identification of the parental origin may be useful to distinguish between the sporadic form of RTT and a potentially
familial form. This distinction will allow geneticists to offer more-specific counseling and discriminate between
higher (maternal origin) and lower (paternal origin) recurrence risk.
Introduction
Rett syndrome (RTT [MIM 312750]) is an X-linked neu-
rodevelopmental disorder that almost exclusively affects
female offspring. It is characterized by mental retarda-
tion, loss of acquired skills (especially purposeful hand
use), and deceleration of head growth. A normal pre-
natal and postnatal development that lasts 8–30 mo is
followed by developmental stagnation and regression of
mental and motor abilities. Diagnostic criteria and dis-
ease stages for RTT were established in 1985 (Hagberg
et al. 1985). Common clinical features include stereo-
typical hand movements, hyperventilation, seizures,
growth retardation, scoliosis, and autonomic dysfunc-
tion. The prevalence of the disease is estimated to be 1/
10,000–1/15,000 female births (Hagberg 1985).
Mutations in MECP2 (MIM 300005) recently have
been described by several groups, with a detection rate
of 25%–90% (Amano et al. 2000; Amir et al. 2000;
Bienvenu et al. 2000; Cheadle et al. 2000; Huppke et
al. 2000; Obata et al. 2000; Xiang et al. 2000). Inter-
estingly, in all studies, a low rate of detection of mu-
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tations has been detected in familial cases of RTT (Amir
et al. 2000; Cheadle et al. 2000; Xiang et al. 2000). No
satisfactory explanation for the discrepancy between de-
tection rates in sporadic cases and detection rates in
familial cases is available. Until now, five reports had
described mutations in the MECP2 gene in male pa-
tients (Wan et al. 1999; Clayton-Smith et al. 2000; Me-
loni et al. 2000; Orrico et al. 2000; Villard et al. 2000).
Four of these reports describe the rare, documented fa-
milial cases of MECP2 mutations: the first describes a
male child affected by congenital encephalopathy who
survived to age 1 year (Wan et al. 1999); the second
describes four adult brothers affected by severe non-
specific mental retardation and movement disorders
(resting tremors and slowness of movements) (Orrico
et al. 2000); the third describes two men affected by
severe mental retardation and progressive spasticity
(Meloni et al. 2000); and the fourth describes two
brothers affected by severe neonatal encephalopathy
who died of severe apnea at age !1 year (Villard et al.
2000). The fifth report describes a sporadic case—a boy
affected by a nonfatal neurodevelopmental disorder
who has a somatic mosaicism in theMECP2 gene (Clay-
ton-Smith et al. 2000). Owing to the paucity of surviv-
ing affected male offspring, mutations in the MECP2
gene are considered developmentally lethal in male em-
bryos. This hypothesis is consistent with the results of
a knockout mouse model for MECP2, in which no vi-
able male animals were born (Tate et al. 1996). Thomas
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(1996), however, hypothesizes a high male:female ratio
of germline mutations for RTT and other X-linked dom-
inant genetic diseases; this hypothesis suggested that the
lack of affected males is due merely to the fact that the
male offspring do not inherit the paternal X chromo-
some. Thomas’s hypothesis implies both that de novo
mutations occur on the paternal X chromosome, which
is inherited only by the female offspring, and that the
affected females have a significant reproductive disad-
vantage; the few female carriers of a mutation in the
MECP2 gene that are able to reproduce account for the
rare familial cases. In this study, to determine the pa-
rental origin of the mutations, we investigated 27 fe-
males with RTT, affected because of de novo mutations
in the MECP2 gene.
Subjects and Methods
Subjects
A total of 144 patients with RTT who carried a mu-
tation in the MECP2 gene were studied for the presence
of frequent polymorphisms in intron 3. The identifica-
tion of intragenic single-nucleotide polymorphisms
(SNPs) relatively near the mutation sites allowed us to
coamplify mutations and SNPs in the same amplicon.
These were subsequently cloned to determine the phase
of the mutation and parental SNP. The group of patients
consisted of 132 German females, 2 Italian females, and
10 Turkish females. Of the 144 patients with RTT, 42
were found to be informative because of heterozygosity
for at least one polymorphism in the MECP2 gene. For
25 patients with RTT, blood samples from both parents
were obtained, with informed consent. In two cases,
blood samples were available only from the mother. Pa-
rental ages at the time of childbirth were obtained from
the clinical files of the patients and were available for
25 fathers and 24 mothers.
Mutation Detection
Total genomic DNA was prepared from peripheral
blood leukocytes according to standard procedures (Mil-
ler et al. 1988). PCR amplification of a 2.3-kb DNA
fragment containing exon 3, intron 3, and exon 4 of the
MECP2 gene, as well as mutation detection in these
products, were performed as described elsewhere (Hu-
ppke et al. 2000). Whenever a mutation created or abol-
ished a cleavage site, it was confirmed by restriction-
enzyme digestion (fig. 1).
Identification of Polymorphic Variants
In a search for polymorphisms in the sequence of the
MECP2 gene, we analyzed intron 3 in 10 patients, by
direct sequencing on an ABI 377 automatic sequencer
with the primer In-RT-F (table 1). In intron 3, at position
c.377266, we found a new frequent SNP (C/T) which
creates a recognition site for restriction enzyme AluI
(AGCC/AGCT). To screen our group of patients for in-
dividuals heterozygous for this polymorphism, we am-
plified the relevant DNA region from patient genom-
ic DNA, with flanking intronic primers, and digested
the product with AluI (table 1). The resulting PCR prod-
uct, 248 bp in length, constitutively contains a recog-
nition site for AluI, at positions 52–55. A second AluI
recognition site, at positions 77–80 of the fragment, is
selectively present in those products created from
c.377266T variant alleles. A further intronic poly-
morphism, c.37817delT, was detected by sequencing
of the 3′ part of intron 3, with the primer Rett Ex3-F1.
In our laboratory, this primer is routinely used for mu-
tation analysis of the amplicon containing exon 4.
Screening for the c.37817delT polymorphism was
done by direct sequencing in all cases. To determine the
allele frequencies of these two intronic polymorphisms,
the allele status was determined for 56 unrelated, healthy
white females, as indicated above. Other intragenic SNPs
recently have been reported in the public dbSNP data-
base and may be useful for analysis of the phase of a
patient’s mutation in cases of noninformative SNPs
(dbSNP accession numbers rs760103, rs1474485,
rs1042870, rs1042873, and rs1474486).
Allele Separation, Linkage Analysis, and Identification
of Parental Origin
Only patients heterozygous for at least one intronic
SNP were selected. Since RTT is an X-linked disorder,
the unequivocal identification of the paternal alleles was
obtained by comparison of the genotypes of the hetero-
zygous patients with those of their hemizygous fathers.
The identity of the maternal alleles was then simply de-
duced. To establish the phase of mutation and the pa-
rental marker allele, 2.3-kb PCR products ranging from
exon 3 to exon 4 and including a patient’s mutation and
informative SNP were cloned into the pGEM-T Easy
Vector (Promega), according to the manufacturer’s in-
structions, and were transformed in pSure Escherichia
coli (Stratagene). For each patient, several colonies were
selected and screened, by colony PCR, for the presence
of the insert with vector-specific primers (table 1). This
procedure resulted in 2.5-kb PCR products in cases with
successful ligation of the 2.3-kb fragment into the
pGEM-T Easy Vector (2.3 kb of specific genomic DNA
 174 bp of vector sequences). Each 2.5-kb PCR prod-
uct resulting from a single colony was then genotyped
for the c.377266CrT polymorphism, by a second-
round PCR, followed either by restriction cutting with
AluI or, in cases of polymorphism for c.37817delT, by
direct sequencing. The same 2.5-kb products were then
tested for the presence of a patient’s mutation (table 1)
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Figure 1 A, Sequence analysis of patient 18, who is heterozygous for mutation R270X (c.808CrT). The wild-type allele shows the
recognition site (GCCG) of the NlaIV restriction enzyme; in the mutant allele, the NlaIV recognition site (GTCG) is abolished. B, Linkage
analysis of mutation R270X in patient 18. The status, at the polymorphic region c.377266CrT of patient 18 and her parents was determined
by amplification of the respective region from genomic DNA and subsequent AluI digestion (lanes 2–4). The patient showed a DNA restriction
pattern with fragments 195 and 169 bp in length (upper bands), indicating heterozygosity for the c.377266CrT polymorphism. The patient’s
father showed a restriction pattern with a 195-bp fragment (missing the 169-bp fragment) indicating that he carries the cytosine variant of the
c.377266CrT polymorphism on his single X chromosome. The patient’s mother showed the same restriction pattern as was seen in the
patient and is also heterozygous for the c.377266CrT polymorphism. Conclusively, in patient 18, the allele containing cytosine must be of
paternal origin, and the allele containing thymine must be of maternal origin. Lanes 6–15 show polymorphism genotyping and mutation detection
in five different clones of patient 18. Clones 1–3 show an AluI restriction pattern indicated by cytosine variant alleles of the c.377266CrT
polymorphism (lanes 6–8), and clones 4 and 5 show a pattern indicated by thymine variant alleles (lanes 9 and 10). Mutation detection in
these five clones was done by second-round PCR and subsequent digestion with NlaIV. Mutant alleles miss an NlaIV cleavage site, at position
490 of the generated 590-bp PCR product, resulting in a DNA fragment that is 191 bp in length (upper band), instead of two smaller fragments.
Clones 1–3 (lanes 11–13) show this 191-bp fragment, and clones 4 and 5 (lanes 14 and 15) do not. Mutation R270X is linked to the cytosine
variant allele of the c.377266CrT polymorphism and therefore is of paternal origin.
to determine the linkage between polymorphism and
mutation. All analyzed colony-PCR products were un-
equivocally hemizygous for the intronic polymorphisms
and for a patient’s mutation or wild-type alleles, as ex-
pected. This highlights the 100% specificity of this ap-
proach, with virtually no mistakes. For each patient, we
analyzed 5–10 clones. In all 27 patients, we were able
to examine clones of both alleles. The parental allele
status for the corresponding intronic polymorphisms
was determined by amplification from genomic DNA,
followed by either restriction-enzyme digestion or direct
sequencing, as indicated in the “Identification of Poly-
morphic Variants” subsection (above).
Results
Allelic Frequencies
In our group of patients (288 alleles), the frequency
of the cytosine variant of the c.377266CrT poly-
morphism in intron 3 was found to be 83%, whereas
the frequency of the thymine variant for that polymor-
phism was found to be 17%. This resulted in a calculated
heterozygosity frequency of 28%; however, we counted
44 heterozygous females in our group of 144 screened
patients (30.5%). The frequency of the TTT variant of
the c.37817delT polymorphism in intron 3 was found
to be ∼99%, and, accordingly, the frequency of the
TT variant was found to be ∼1%. Three patients in
our group were heterozygous for the c.37817delT
polymorphism.
Fifty-six healthy control females were screened for
both polymorphisms. In this sample (112 alleles), the
frequency of the cytosine variant of the c.377266CrT
polymorphism was found to be 77%, whereas the fre-
quency of the thymine variant was found to be 23%.
None of the females in the control group carried the
c.37817delT allele. The differences, in allelic frequen-
cies, between the control group and the group of patients
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are not statistically significant ( for theP 1 .15
c.377266CrT polymorphism, ; and2x p 2.04 P 1
for the c.37817delT polymorphism, ).2.27 x p 1.18
Spectrum of Analyzed Mutations—and Their Linkage
to Intronic Polymorphisms
In a total of 27 patients, we analyzed 15 different
mutations in the MECP2 gene to examine the parental
origin of de novo mutations in RTT; 9 patients had
missense mutations, 14 had nonsense mutations, 1 had
a splice-site mutation, 1 had a small insertion, and 2
had a deletion in exon 4 (one deletion was 44 bp and
the other was 156 bp). The analysis of linkage between
the intronic polymorphism c.377266CrT and the
different mutations in the MECP2 gene revealed link-
age of the mutation to the cytosine variant allele in 16
patients and to the thymine variant allele in 9 patients.
On the basis of the allelic frequencies for the
c.377266CrT polymorphism in our control group, we
predicted the linkage of mutations to the cytosine variant
allele to be three times more frequent than that to the
thymine variant allele. In fact, the proportion of mu-
tations linked to thymine variant alleles was slightly
higher than expected (i.e., nine, instead of six), but this
difference did not reach statistical significance ( ,P 1 .35
). Thus, our results do not indicate a prefer-2x p 0.86
ence of de novo mutations, for either of the polymorphic
variants. With respect to the c.37817delT polymor-
phism, the mutation in the MECP2 gene was always
detected on the TTT allele, which is the much more
frequent allele; however, only two patients were ana-
lyzed for this polymorphism.
Origin of Mutation
Of the 27 patients, 26 showed a paternal origin of
mutation. This predominance of paternal origin is highly
significant ( , ). Furthermore, the pa-2P ! .001 x p 13.89
ternal origin was independent of the type and localiza-
tion of mutation and was found in point mutations as
well as in deletions 156 bp. A detailed analysis of the
origin of mutations for all patients analyzed is shown
in table 2.
The only patient showing maternal origin revealed a
missense mutation (R133C) in the MBD of the MECP2-
gene product. The same mutation was found in two cases
with paternal origin of mutations. Mixing up the DNA
probes of father and mother was excluded by Y-specific
PCR and X-specific amplification of the highly poly-
morphic androgen-receptor gene. The patient’s mother
did not carry the mutation, at least in the DNA derived
from blood leukocytes.
Parental Ages
The mean parental ages at the time of childbirth were
determined for the families with paternal origin of mu-
tation. The mean paternal age was years, and31.3 4.5
the mean maternal age was years, with28.2 4.4
ranges of 23–42 years and 22–36 years, respectively. In
the single case of maternal origin, the mother was aged
25 years, and the father was aged 34. During the past
10 years, the range in mean maternal age at the time of
childbirth for the German population has been 27–30
years, and the age at childbirth continuously rose during
this period of time; also during the past 10 years,
German men have been, on average, 2.86 years older
than their partners at time of marriage (Statistisches Bun-
desamt Wiesbaden 1985–99). In parents of patients with
RTT, neither paternal age nor maternal age differed sig-
nificantly from that for the German population in
general.
Discussion
Paternal Origin of Mutations in RTT: Almost
Exclusively Female Affection
Along with RTT, there are at least 13 X-linked domi-
nant diseases that are caused by de novo mutations and
that have a supposedly lethal phenotype in males and
that result in reproductive disadvantage in affected fe-
males (Thomas 1996). Male lethality is the traditional
explanation for the pronounced majority of affected fe-
males and, in some cases, the almost total absence of
affected males (Wettke-Scha¨fer and Kantner 1983). In
1996, Thomas proposed a simple alternative to this the-
ory: he suggested a very high male:female ratio of de
novo mutations (Thomas 1996). According to this
model, males are protected from X-linked dominant dis-
eases because they do not inherit the mutation-prone
paternal X chromosome. Our investigation of the pa-
rental origin of the MECP2 mutations in patients with
sporadic RTT clearly gives strong evidence that, in al-
most all (26 of 27) cases, de novo mutations in the
MECP2 gene arise on the paternal X chromosome. We
suggest that males are, therefore, naturally protected
from the sporadic form of RTT, which is caused by de
novo mutations, and that RTT should no longer be con-
sidered lethal in males. A corollary of this hypothesis is
that the affected males would inherit their X chromo-
some from their mothers, who are carriers, or that the
mutation arises de novo on the maternal chromosome.
In fact, mutations in the MECP2 gene recently have been
described in males in four familial cases: a male child
affected by congenital encephalopathy who survived to
age 1 year (Wan et al. 1999), four adult brothers af-
fected by severe nonspecific mental retardation and
movement disorders (resting tremors and slowness of
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Table 2
The Parental Origin of MECP2 Mutations in Sporadic RTT
MUTATION TYPE AND
PATIENT NUMBER PATIENT MUTATION
INTRAGENIC
SNP
SNP GENOTYPEa
PHASE OF
MUTATION
ORIGIN OF
MUTATIONPaternalb Maternal Patient
Missense:
1 316CrT 377266CrT C T/T C/T C Paternal
2 397CrT 377266CrT C T/T C/T C Paternal
3 397CrT 377266CrT n.a. C/C C/T T Paternal
4 455CrG 377266CrT T C/C C/T T Paternal
5 467ArG 377266CrT C C/T C/T C Paternal
6 473CrT 377266CrT T C/C C/T T Paternal
7 473CrT 37817delT TTT TT/TTT TT/TTT TTT Paternal
8 916CrT 377266CrT C C/T C/T C Paternal
Nonsense:
9 502CrT 377266CrT C C/T C/T C Paternal
10 502CrT 377266CrT T C/T C/T T Paternal
11 502CrT 377266CrT n.a. C/C C/T T Paternal
12 502CrT 377266CrT C T/T C/T C Paternal
13 502CrT 37817delT TTT TT/TTT TT/TTT TTT Paternal
14 502CrT 377266CrT T C/C C/T T Paternal
15 613GrT 377266CrT C C/T C/T C Paternal
16 763CrT 377266CrT C C/T C/T C Paternal
17 763CrT 377266CrT C T/T C/T C Paternal
18 808CrT 377266CrT C C/T C/T C Paternal
19 808CrT 377266CrT T C/C C/T T Paternal
20 808CrT 377266CrT C C/T C/T C Paternal
21 880CrT 377266CrT C T/T C/T C Paternal
22 880CrT 377266CrT T C/C C/T T Paternal
Splice site:
23 3782ArG 377266CrT C T/T C/T C Paternal
Insertions/deletions:
24 718insC 377266CrT T C/C C/T T Paternal
25 1154–1198del 377266CrT C C/T C/T C Paternal
26 1039–1195delinsGT 377266CrT C C/T C/T C Paternal
Missense:
27 397CrT 377266CrT C T/T C/T T Maternal
a Only patients heterozygous for an intronic SNP were selected. Because RTT is an X-linked disorder, the unequivocal identification of a
patient’s paternal allele was obtained by comparison of her SNP genotypes with those of her father; the genotypes compared are in boldface
italic type. The patient’s second allele must then be maternally derived.
b n.a. p Not available; however, in these cases, homozygosity for the cytosine variant allele in the patients’ mothers allows identification of
the patients’ thymine variant allele to be paternally derived.
movements) (Orrico et al. 2000), two men affected by
severe mental retardation and progressive spasticity
(Meloni et al. 2000), and two brothers affected by severe
neonatal encephalopathy who died of severe apnea at
age !1 year (Villard et al. 2000). In a further case, a
postzygotic mutation most probably arose de novo on
the maternal chromosome (Clayton-Smith et al. 2000)
and confirms the viability of both possible causes ac-
counting for affected males: inheritance of the affected
alleles from carrier mothers and de novo mutations on
maternal X chromosomes.
Studies on the parental origin of de novo mutations
have been done both for autosomal dominant diseases,
such as Apert syndrome (Moloney et al. 1996) and Crou-
zon syndrome (Glaser et al. 2000) and for tumor-asso-
ciated diseases, such as MEN-2B (Carlson et al. 1994)
and NF-1 (Jadayel et al. 1990). The exclusively paternal
origin of de novo mutations has been proved for Apert
syndrome, Crouzon syndrome, and MEN-2B. In case of
NF-1, the paternal origin of de novo mutations has been
proved to be highly predominant. An increased paternal
age, however, has been documented only for Apert syn-
drome and Crouzon syndrome. In these diseases, the
exclusively paternal mutation rate might correlate pos-
itively with the number of cell divisions of the sper-
matogonia. This mechanism cannot be responsible for
the high male:female ratio of de novo mutations in RTT,
because there is no increment in the paternal age in fa-
thers of patients with RTT. The underlying mechanisms
for the increased male mutation rate are not clear. The
different activation state of the X chromosome in the
oocytes and in the spermatocytes is a distinctive element
for the two germ lines. The X chromosome in oocytes
is undermethylated, whereas the X chromosome in
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sperm is hypermethylated because of the epigenetic mod-
ification associated with the process of chromatin in-
activation (Goto and Monk 1998). It has been suggested
that a spontaneous deamination of the 5m-cytosine res-
idue at position 4 of the carbon ring may result in the
conversion to a thymine (Goto and Monk 1998). As a
matter of fact, ∼70% of the mutations in the MECP2
gene are cytosine-to-thymine transitions (Dragich et al.
2000), and this is consistent with the possibility of hy-
permutability at methylated CpG dinucleotides. How-
ever, this mechanism cannot account for the other types
of mutations in MECP2, such as deletions or transver-
sions, that also arise on the paternal X chromosome. It
may be possible that the mutation rate, independently
of the kind of mutation, does not differ as much as
supposed in the female and male germ line. Recently, in
fact, Bohossian et al. (2000) questioned the hypothesis
of a higher mutation rate in males and found a male:
female mutation rate of 1.7. If these findings are also
applicable to mutations in the MECP2 gene, then the
observed bias with respect to the parental origin of the
mutations should be a postmutational event. It may be
possible that mutations on the female X chromosome
are detrimental to the oocytes expressing the mutated
protein. This mechanism would reduce the likelihood
that oocytes with a mutation of the MECP2 gene would
be fertilized. Only a few oocytes escaping this selection
would then account for cases of RTT that are due to de
novo mutation on the maternal X chromosome. This
hypothesis, however, is partially invalidated by the fa-
milial cases of RTT in which healthy mothers either are
obligate carriers of a germline mutation or have a con-
stitutive mutation of the MECP2 gene. The different
epigenetic situation of the male and female X chromo-
somes in germ cells may, however, be a key point for
understanding the different behavior regarding the mu-
tation rate of the MECP2 gene.
Mutations of Maternal Origin—and the Consequences
for Genetic Counseling
Until now, in all known familial cases with inheritance
of MECP2 mutations, the mother has been found either
to be carrier of the mutation (Amir et al. 1999, 2000;
Wan et al. 1999; Cheadle et al. 2000; Meloni et al. 2000;
Orrico et al. 2000) or to carry a mosaicism for the mu-
tation (Amir et al. 1999). In contrast, a recurrent
MECP2 mutation inherited through the paternal germ
line had, until now, never been described in patients with
RTT. Our findings demonstrate a very high predomi-
nance of paternal origin of MECP2 mutations in spo-
radic cases of RTT. This, along with the above-men-
tioned familial cases of MECP2 mutations due to
exclusively maternal inheritance, suggests that mutations
appearing on maternal alleles might have a higher risk
to cause familial cases of RTT. A proportion of these
alleles will represent de novo mutations on the maternal
X chromosome, but some of them may be due to a
maternally inherited mutation that, because of either
skewed X inactivation or mosaicism, does not induce an
evident phenotype in the carrier mother. We speculate
that, in such cases of maternally inherited MECP2 mu-
tations, the primary mutational event appeared on the
mother’s paternal X chromosome. The recent report by
Villard et al. (2000) describes a family with two affected
male children and with a female child with typical RTT,
in all of whom the T151M mutation is due to inheritance
of a mutated allele from the mother. Consistent with our
hypothesis of a prevalent mutational event on the pa-
ternal chromosomes is the finding that the MECP2 mu-
tation in this family is, in fact, located on the mother’s
paternal X chromosome.
We therefore suggest that MECP2 mutations of ma-
ternal origin should be considered to have a recurrence
risk higher than that in MECP2 mutations of paternal
origin. After exclusion of the respective mutation in ma-
ternal DNA derived from blood leukocytes, we suggest
analysis of parental origin of the mutated allele, to es-
timate the possible recurrence risk due to potential ma-
ternal mosaicism. Then, if the analysis of polymorphic
markers reveals a maternal origin of the mutated allele,
it may be advisable to investigate DNA from the mother
that is derived from additional tissues (such as gingiva
cells and fibroblasts). The identification of mosaicism in
the mother would, of course, lead to prediction of a
recurrence risk of as much as 50%. However, indepen-
dent of a detectable mosaicism, we consider the few cases
in which the mutations arise on the maternal chromo-
some to be at a higher recurrence risk, because germ-
cell mosaicism cannot be excluded. In contrast, if, as in
the majority of cases, a paternal origin of mutation is
found, then the recurrence risk may be low, since the
paternal origin of MECP2 mutations has been shown
to be the usual condition of the sporadic form of RTT
and, until now, has never been described in familial cases
of RTT. Nevertheless, the possibility of paternal germline
mosaicism in the MECP2 gene cannot generally be ex-
cluded a priori. In some sporadic cases, a paternal germ-
line mosaicism has been described for autosomal dis-
orders, such as neurofibromatosis type 1 (Lazaro et al.
1994) and osteogenesis imperfecta (Cohn et al. 1990;
Edwards et al. 1992; Namikawa et al. 1995). The ge-
notyping of DNA from sperm cells of fathers of patients
with RTT may be a useful approach for analysis of a
potential male germline mosaicism. Although we con-
sider the recurrence risk to be low for MECP2mutations
of paternal origin, prenatal diagnosis should be dis-
cussed and provided if requested.
In conclusion, our findings give strong evidence that
there is male sparing in RTT—and not necessarily male
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lethality, as previously has been supposed. The identi-
fication of a mutation arising on the maternal chro-
mosome may reveal a potentially familial form of RTT.
The analysis of parental origin of the underlying mu-
tations may therefore be beneficial to families of patients
with RTT.
Acknowledgments
We thank the patients with RTT, as well as their parents,
for their participation; S. Buth, S. Herlt, U. Lenz, A. Herwig,
and K. Ru¨cker for their technical contribution; and Elternhilfe
fu¨r Kinder mit Rett Syndrom.
Electronic-Database Information
Accession numbers and URLs for data in this article are as
follows:
dbSNP, http://www.ncbi.nlm.nih.gov/SNP/ (for intragenic
SNPs, accession numbers rs760103, rs1474485, rs1042870,
rs1042873, and rs1474486)
Online Mendelian Inheritance in Man (OMIM), http://www
.ncbi.nlm.nih.gov/Omim/ (for MECP2 [MIM 300005] and
RTT [MIM 312750])
References
Amano K, Nomura Y, Segawa M, Yamakawa K (2000) Mu-
tational analysis of the MECP2 gene in Japanese patients
with Rett syndrome. J Hum Genet 45:231–236
Amir RE, Van den Veyver IB, Schultz R, Malicki DM, Tran
CQ, Dahle EJ, Philippi A, Timar L, Percy AK, Motil KJ,
Lichtarge O, Smith EO, Glaze DG, Zoghbi HY (2000) In-
fluence of mutation type and X chromosome inactivation
on Rett syndrome phenotypes. Ann Neurol 47:670–679
Amir RE, Van den Veyver IB, Wan M, Tran CQ, Francke U,
Zoghbi HY (1999) Rett syndrome is caused by mutations
in X-linked MECP2, encoding methyl-CpG-binding protein
2. Nat Genet 23:185–188
Bienvenu T, Carrie A, de Roux N, Vinet MC, Jonveaux P,
Couvert P, Villard L, Arzimanoglou A, Beldjord C, Fontes
M, Tardieu M, Chelly J (2000) MECP2 mutations account
for most cases of typical forms of Rett syndrome. Hum Mol
Genet 9:1377–1384
Bohossian HB, Skaletsky H, Page DC (2000) Unexpectedly
similar rates of nucleotide substitution found in male and
female homonids. Nature 406:622–625
Carlson KM, Bracamontes J, Jackson CE, Clark R, Lacroix
A, Wells SA Jr, Goodfellow PJ (1994) Parent-of-origin effects
in multiple endocrine neoplasia type 2B. Am J Hum Genet
55:1076–1082
Cheadle JP, Gill H, Fleming N, Maynard J, Kerr A, Leonard
H, Krawczak M, Cooper DN, Lynch S, Thomas N, Hughes
H, Hulten M, Ravine D, Sampson JR, Clarke A (2000)
Long-read sequence analysis of the MECP2 gene in Rett
syndrome patients: correlation of disease severity with mu-
tation type and location. Hum Mol Genet 9:1119–1129
Clayton-Smith J, Watson P, Ramsden S, Black GCM (2000)
Somatic mutation in MECP2 as a non-fatal neurodevelop-
mental disorder in males. Lancet 356:830–832
Cohn DH, Starman BJ, Blumberg B, Byers PH (1990) Recur-
rence of lethal osteogenesis imperfecta due to parental mo-
saicism for dominant mutation in a human type I collagen
gene (COL1A1). Am J Hum Genet 46:591–601
Dragich J, Houwink-Manville I, Schanen C (2000) Rett syn-
drome: a surprising result of mutation in MECP2. Hum Mol
Genet 9:2365–2375
Edwards MJ, Wenstrup RJ, Beyers PH, Cohen DH (1992)
Recurrence of lethal osteogenesis imperfecta due to parental
mosaicism for a mutation in the COL1A2 gene of type I
collagen: the mosaic parent exhibits phenotypic features of
mild form of the disease. Hum Mutat 1:47–54
Glaser RL, Jiang W, Boyadjiev SA, Tran AK, Zachary AA, Van
Maldergem L, Johnson D, Walsh S, Oldridge M, Wall SA,
Wilkie AO, Jabs EW (2000) Paternal origin of FGFR2 mu-
tations in sporadic cases of Crouzon syndrome and Pfeiffer
syndrome. Am J Hum Genet 66:768–777
Goto T, Monk M (1998) Regulation of X-chromosome in-
activation in development in mice and humans. Microbiol
Mol Biol Rev 62:362–378
Hagberg B (1985) Rett’s syndrome: prevalence and impact on
progressive severe mental retardation in girls. Acta Paediatr
Scand 74:405–408
Hagberg B, Goutieres F, Hanefeld F, Rett A, Wilson J (1985)
Rett syndrome: criteria for inclusion and exclusion. Brain
Dev 7:372–373
Huppke P, Laccone F, Kramer N, Engel W, Hanefeld F (2000)
Rett syndrome: analysis of MECP2 and clinical character-
ization of 31 patients. Hum Mol Genet 9:1369–1375
Jadayel D, Fain P, Upadhyaya M, Ponder MA, Huson SM,
Carey J, Fryer A, Mathew CG, Barker DF, Ponder BA (1990)
Paternal origin of new mutations in von Recklinghausen
neurofibromatosis. Nature 343:558–559
Lazaro C, Ravella A, Gaona A, Volpini V, Estivill X (1994)
Neurofibromatosis type 1 due to germ-line mosaicism in a
clinically normal father. N Engl J Med 331:1403–1407
Meloni I, Bruttini M, Longo I, Mari F, Rizzolio F, D’Adamo
P, Denvriendt K, Fryns JP, Toniolo D, Renieri A (2000) A
mutation in the Rett syndrome gene, MECP2, causes X-
linked mental retardation and progressive spasticity in
males. Am J Hum Genet 67:982–985
Miller SA, Dykes DD, Polesky HF (1988) A simple salting out
procedure for extracting DNA from human nucleated cells.
Nucleic Acids Res 16:1215
Moloney DM, Slaney SF, Oldrige M, Wall SA, Sahlin P, Sten-
man G, Wildie AO (1996) Exclusive paternal origin of new
mutations in Apert syndrome. Nat Genet 13:9–10
Namikawa C, Suzumori K, Fukushima Y, Sasaki M, Hata A
(1995) Recurrence of osteogenesis imperfecta because of pa-
ternal mosaicism: Gly862rSer substitution in a type I col-
lagen gene (COL1A1). Hum Genet 95:666–670
Obata K, Matsuishi T, Yamashita Y, Fukuda T, Kuwajima K,
Horiuchi I, Nagamitsu S, Iwanaga R, Kimura A, Omori I,
Endo S, Mori K, Kondo I (2000) Mutation analysis of the
methyl-CpG binding protein 2 gene (MECP2) in patients
with Rett syndrome. J Med Genet 37:608–610
Orrico A, Lam C, Galli L, Dotti MT, Hayek G, Tong SF, Poon
PM, Zappella M, Federico A, Sorrentino V (2000) MECP2
Trappe et al.: Origin of MECP2 Mutations in RTT 1101
mutation in male patients with non-specific X-linked mental
retardation. FEBS Lett 481:285–288
Statistisches Bundesamt Wiesbaden (1985–99) Statistisches
Jahrbuch fu¨r die Bundesrepublik Deutschland. Metzler-
Poeschel, Stuttgart
Tate P, Skarnes W, Bird A (1996) The methyl-CpG binding
protein MeCP2 is essential for embryonic development in
the mouse. Nat Genet 12:205–208
Thomas GH (1996) High male:female ratio of germ-line mu-
tations: an alternative explanation for postulated gestational
lethality in males in X-linked dominant disorders. Am J
Hum Genet 58:1364–1368
Villard L, Cardoso AK, Chelly PJ, Tardieu PM, Fontes M
(2000) Two affected boys in a Rett syndrome family: clinical
and molecular findings. Neurology 55:1188–1193
Wan M, Lee SS, Zhang X, Houwink-Manville I, Song HR,
Amir RE, Budden S, Naidu S, Pereira JL, Lo IF, Zoghbi HY,
Schanen NC, Francke U (1999) Rett syndrome and beyond:
recurrent spontaneous and familial MECP2 mutations at
CpG hotspots. Am J Hum Genet 65:1520–1529
Wettke-Scha¨fer R, Kantner G (1983) X-linked dominant in-
herited diseases with lethality in hemizygous males. Hum
Genet 64:1–23
Xiang F, Buervenich S, Nicolao P, Bailey ME, Zhang Z, Anvret
M (2000) Mutation screening in Rett syndrome patients. J
Med Genet 37:250–255
